Literature DB >> 19463875

Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.

Nieves González1, Samuel A Mantey, Tapas K Pradhan, Veronica Sancho, Terry W Moody, David H Coy, Robert T Jensen.   

Abstract

The mammalian bombesin (Bn) peptides neuromedin B (NMB) and gastrin-releasing peptide (GRP) actions are mediated by two receptors (NMB-receptor, GRP-receptor) which are widely distributed in the GI tract and CNS. From primarily animal studies NMB/GRP-receptor activation has physiological/pathophysiological effects in the CNS and GI tract including stimulating of growth of cancers and normal tissues. Whereas these Bn-receptors' effects have been extensively studied in nonhuman cells and animals, little is known of the physiological/pathological role(s) in humans, largely due to lack of potent antagonists. To address this issue we compared NMB/GRP-receptor affinity/potency of 10 chemical classes of putative antagonists (35 compounds) for human Bn-receptors by performing binding studies or assessing abilities to activate hGRP/hNMB-receptor [assessing phospholipase C activation] in four different cells containing native Bn-receptors or transfected receptors. From binding studies 23 were GRP-receptor-preferring, 4 were NMB-receptor, and 8 nonselective. For the hGRP-receptor-preferring analogues none showed hGRP-receptor agonist activity, but 13 were full or partial hNMB-receptor agonists at hNMB-receptors. For hNMB-receptor-preferring analogues none were agonists. Analogue #24 ([(3-Ph-Pr(6)), His(7), d-Ala(11), d-Pro(13), Psi(13-14), Phe(14)]Bn(6-14)NH2) and analogue #7 [d-Phe(6), Leu(13), Psi(CH(2)NH), Cpa(14)]Bn(6-14) were the most potent (0.2-1.4nM) and selective (>10,000-fold) for the hGRP-receptor with analogue #7.5 [d-Tpi(6), Leu(13), Psi(CH2NH), Leu(14)]Bn(6-14)[RC-3095] (0.2-1.4nM) slightly less selective. Analogue #34 (PD168368) had the highest affinity for hNMB-receptor (1.32-1.58nM) and the greatest selectivity (2298-6952-fold) for the hNMB-receptor. These results demonstrate numerous putative hGRP/hNMB-receptor antagonists identified in nonhuman cells and/or animals have agonist activity at the hNMB-receptor, limiting their potential usefulness. However, a number were identified which were potent/selective for human Bn-receptors and should be useful for investigating their roles in human physiological/pathophysiological conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19463875      PMCID: PMC2766550          DOI: 10.1016/j.peptides.2009.05.007

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  62 in total

1.  Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity.

Authors:  D H Coy; J E Taylor; N Y Jiang; S H Kim; L H Wang; S C Huang; J P Moreau; J D Gardner; R T Jensen
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

2.  Effect of substitutions in position 12 of bombesin on antagonist activity.

Authors:  Z A Saeed; S C Huang; D H Coy; N Y Jiang; P Heinz-Erian; S Mantey; J D Gardner; R T Jensen
Journal:  Peptides       Date:  1989 May-Jun       Impact factor: 3.750

3.  Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells.

Authors:  L H Wang; D H Coy; J E Taylor; N Y Jiang; S H Kim; J P Moreau; S C Huang; S A Mantey; H Frucht; R T Jensen
Journal:  Biochemistry       Date:  1990-01-23       Impact factor: 3.162

4.  des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists.

Authors:  L H Wang; D H Coy; J E Taylor; N Y Jiang; J P Moreau; S C Huang; H Frucht; B M Haffar; R T Jensen
Journal:  J Biol Chem       Date:  1990-09-15       Impact factor: 5.157

5.  Neuromedin B receptor in esophagus: evidence for subtypes of bombesin receptors.

Authors:  T Von Schrenck; P Heinz-Erian; T Moran; S A Mantey; J D Gardner; R T Jensen
Journal:  Am J Physiol       Date:  1989-04

6.  Potent bombesin receptor antagonists distinguish receptor subtypes.

Authors:  T von Schrenck; L H Wang; D H Coy; M L Villanueva; S Mantey; R T Jensen
Journal:  Am J Physiol       Date:  1990-09

Review 7.  Progress in the development of potent bombesin receptor antagonists.

Authors:  R T Jensen; D H Coy
Journal:  Trends Pharmacol Sci       Date:  1991-01       Impact factor: 14.819

8.  Characterization of ability of various substance P antagonists to inhibit action of bombesin.

Authors:  R T Jensen; P Heinz-Erian; S Mantey; S W Jones; J D Gardner
Journal:  Am J Physiol       Date:  1988-06

9.  Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity.

Authors:  D H Coy; P Heinz-Erian; N Y Jiang; Y Sasaki; J Taylor; J P Moreau; W T Wolfrey; J D Gardner; R T Jensen
Journal:  J Biol Chem       Date:  1988-04-15       Impact factor: 5.157

10.  Short chain bombesin pseudopeptides with potent bombesin receptor antagonist activity in rat and guinea pig pancreatic acinar cells.

Authors:  D Coy; L H Wang; N Y Jiang; R Jensen
Journal:  Eur J Pharmacol       Date:  1990-11-06       Impact factor: 4.432

View more
  25 in total

1.  Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.

Authors:  Veronica Sancho; Terry W Moody; Samuel A Mantey; Alessia Di Florio; Hirotsugu Uehara; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2010-05-12       Impact factor: 3.750

2.  The role of central gastrin-releasing peptide and neuromedin B receptors in the modulation of scratching behavior in rats.

Authors:  Pin-Yen Su; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2011-03-18       Impact factor: 4.030

Review 3.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

Review 4.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 5.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

6.  Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.

Authors:  Hirotsugu Uehara; Nieves González; Veronica Sancho; Samuel A Mantey; Bernardo Nuche-Berenguer; Tapas Pradhan; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2011-06-28       Impact factor: 3.750

7.  The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Authors:  Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen
Journal:  Biochem Pharmacol       Date:  2012-07-22       Impact factor: 5.858

8.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.

Authors:  Mariane Jaeger; Carolina Nör; Caroline Brunetto de Farias; Ana Lucia Abujamra; Gilberto Schwartsmann; Algemir Lunardi Brunetto; Rafael Roesler
Journal:  Childs Nerv Syst       Date:  2013-10-03       Impact factor: 1.475

10.  Isolation, identification and biological activity of gastrin-releasing peptide 1-46 (oGRP 1-46), the primary GRP gene-derived peptide product of the pregnant ovine endometrium.

Authors:  A S Giraud; C Dumesny; J C Whitley; L M Parker; I Jennings; B Kemp; T W Moody; V Sancho; R T Jensen; A Shulkes
Journal:  Peptides       Date:  2009-11-26       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.